Department of Dermatology, The Second Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China; Yale School of Medicine, New Haven, Connecticut.
Department of Molecular Biophysics and Biochemistry, Yale School of Medicine, New Haven, Connecticut.
J Am Acad Dermatol. 2017 Sep;77(3):497-502.e2. doi: 10.1016/j.jaad.2017.04.1137. Epub 2017 Jun 20.
Studies have shown contradictory results regarding the survival outcomes among white, African American, and Asian patients with mycosis fungoides (MF).
To evaluate the survival outcomes among white, African American, and Asian patients with MF and to determine other prognostic factors of the disease.
The US National Cancer Database was used to identify patients with histologically confirmed MF from 2004 to 2014. Clinicopathologic, socioeconomic, and treatment data were compared among the races by using the chi-square test. Overall survival was evaluated by using the log-rank test, multivariable Cox proportional hazard regression, and propensity score-matched analysis.
Of 4459 patients with MF, 77.7% were white, 19.2% were African American, and 3.2% were Asian. Older age, treatment received in a community facility, government insurance, higher Charlson-Deyo score, male sex, higher clinical stage, receipt of radiotherapy or chemotherapy, and African American race were predictors of poor overall survival on multivariate analysis (P < .001), whereas Asian race trended toward improved outcomes (P = .07).
Retrospective analysis.
African American patients with MF demonstrated poorer survival than white patients after accounting for disease characteristics, socioeconomic factors, and types of treatment, warranting further investigation into the underlying biology of MF and prescribed treatment modalities.
多项研究表明,在患有蕈样真菌病(MF)的白种人、非裔美国人和亚洲患者中,生存结果存在相互矛盾的结果。
评估 MF 白种人、非裔美国人和亚洲患者的生存结果,并确定该疾病的其他预后因素。
使用美国国家癌症数据库(National Cancer Database),从 2004 年至 2014 年确定组织学确诊 MF 的患者。通过卡方检验比较不同种族间的临床病理、社会经济和治疗数据。通过对数秩检验、多变量 Cox 比例风险回归和倾向评分匹配分析评估总生存率。
在 4459 名 MF 患者中,77.7%为白种人,19.2%为非裔美国人,3.2%为亚洲人。年龄较大、在社区医疗机构接受治疗、政府保险、较高的 Charlson-Deyo 评分、男性、较高的临床分期、接受放疗或化疗以及非裔美国人种族是多变量分析中总生存不良的预测因素(P<0.001),而亚洲种族的结果则倾向于改善(P=0.07)。
回顾性分析。
在考虑疾病特征、社会经济因素和治疗类型后,非裔美国 MF 患者的生存结果比白人患者差,这需要进一步研究 MF 的潜在生物学和规定的治疗方式。